Literature DB >> 6609115

Peripheral T cell lymphoma (immunoblastic sarcoma of T cell type): an immuno-ultrastructural study.

J W Said, I P Shintaku, K Chien, A F Sassoon.   

Abstract

Use of monoclonal antibodies directed against T cell antigens for the phenotypic characterization of neoplastic lymphoid cells in peripheral T cell lymphomas is described. Studies of cryostat sections revealed the distribution of T cell subsets in nodal and extranodal infiltrates, and immuno-ultrastructural techniques demonstrated discrete localization of T cell antigens to the cytoplasmic membranes of neoplastic cells. Although histologically similar, the tumors appeared heterogeneous as to their immunologic phenotype, with the majority demonstrating markers for T helper/inducer lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609115     DOI: 10.1016/s0046-8177(84)80029-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Correlated ultrastructural and immunological findings in CD8+ and CD4+ peripheral T-cell lymphomas.

Authors:  F Osculati; S Cinti; M Reynès; G Balercia; C Canon; V Tricottet; D Dantchev; G Mathé
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  Leu-M1--a marker for Reed-Sternberg cells in Hodgkin's disease. An immunoperoxidase study of paraffin-embedded tissues.

Authors:  G S Pinkus; P Thomas; J W Said
Journal:  Am J Pathol       Date:  1985-05       Impact factor: 4.307

3.  Immunopathology of cutaneous T-cell lymphomas.

Authors:  K Nasu; J Said; E Vonderheid; J Olerud; D Sako; M Kadin
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

4.  Hodgkin's disease, lymphocyte predominance type, nodular--a distinct entity? Unique staining profile for L&H variants of Reed-Sternberg cells defined by monoclonal antibodies to leukocyte common antigen, granulocyte-specific antigen, and B-cell-specific antigen.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1985-01       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.